Compounded off-label glaucoma therapies can reduce medication prices and lead to more widespread treatment, according to a speaker.
The FDA has curbed an initiative to have all effective but unapproved compounded drugs approved by the agency, Wiley A. Chambers, MD, supervisory medical officer of new drugs at the FDA, said at the virtual Glaucoma 360 New Horizons Forum.
“The downside we found in many cases was when old products were approved and came to the market with a new drug application, there would be a rise in the price to (Read more...)
Uncategorized